A collaborative team led by the Broad Institute successfully employed prime editing to correct five distinct mutations responsible for alternating hemiplegia of childhood (AHC) in mouse models. Treated mice exhibited reduced symptoms and doubled survival compared to untreated controls. This represents the first demonstration of prime editing for neurological disease treatment in vivo and offers a potential blueprint for addressing other rare genetic disorders.